ALNY Alnylam Pharmaceuticals Inc

Price (delayed)

$144.20

Market cap

$16.87B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.46

Enterprise value

$16.9B

Sector: Healthcare
Industry: Biotechnology

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is ...

Highlights

The company's revenue has surged by 124% YoY and by 23% QoQ
The gross profit has soared by 113% YoY and by 24% from the previous quarter
The debt has soared by 72% YoY and by 58% from the previous quarter
The equity has contracted by 29% YoY and by 16% from the previous quarter

Key stats

What are the main financial stats of ALNY
Market
Shares outstanding
117M
Market cap
$16.87B
Enterprise value
$16.9B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
16.49
Price to sales (P/S)
33.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.28
Earnings
Revenue
$492.85M
EBIT
-$771.1M
EBITDA
-$696.67M
Free cash flow
-$685.32M
Per share
EPS
-$7.46
Free cash flow per share
-$5.96
Book value per share
$8.75
Revenue per share
$4.29
TBVPS
$29.63
Balance sheet
Total assets
$3.41B
Total liabilities
$2.39B
Debt
$521.19M
Equity
$1.02B
Working capital
$2.03B
Liquidity
Debt to equity
0.51
Current ratio
4.47
Quick ratio
3.38
Net debt/EBITDA
-0.04
Margins
EBITDA margin
-141.4%
Gross margin
84.2%
Net margin
-174.1%
Operating margin
-168.1%
Efficiency
Return on assets
-27.8%
Return on equity
-68.9%
Return on invested capital
-30.8%
Return on capital employed
-27.3%
Return on sales
-156.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALNY stock price

How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
-5.39%
1 week
-4.87%
1 month
-4.66%
1 year
29.42%
YTD
10.95%
QTD
10.95%

Financial performance

How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$492.85M
Gross profit
$414.8M
Operating income
-$828.44M
Net income
-$858.28M
Gross margin
84.2%
Net margin
-174.1%
The company's revenue has surged by 124% YoY and by 23% QoQ
The gross profit has soared by 113% YoY and by 24% from the previous quarter
The company's operating margin has surged by 61% YoY and by 28% QoQ
The net margin has soared by 57% YoY and by 22% from the previous quarter

Growth

What is Alnylam Pharmaceuticals's growth rate over time

Valuation

What is Alnylam Pharmaceuticals stock price valuation
P/E
N/A
P/B
16.49
P/S
33.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.28
ALNY's EPS is up by 8% year-on-year and by 4.8% since the previous quarter
ALNY's price to book (P/B) is 126% more than its 5-year quarterly average of 7.3 and 32% more than its last 4 quarters average of 12.5
The equity has contracted by 29% YoY and by 16% from the previous quarter
The company's revenue has surged by 124% YoY and by 23% QoQ
ALNY's price to sales (P/S) is 65% lower than its 5-year quarterly average of 95.3 and 18% lower than its last 4 quarters average of 41.2

Efficiency

How efficient is Alnylam Pharmaceuticals business performance
ALNY's return on sales has surged by 61% year-on-year and by 25% since the previous quarter
ALNY's return on invested capital is up by 44% year-on-year and by 17% since the previous quarter
The return on assets has increased by 24% year-on-year and by 11% since the previous quarter
The ROE has contracted by 23% YoY and by 4.4% from the previous quarter

Dividends

What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALNY.

Financial health

How did Alnylam Pharmaceuticals financials performed over time
The total assets is 43% more than the total liabilities
The company's total liabilities has surged by 150% YoY and by 14% QoQ
The total assets has increased by 42% YoY and by 3% from the previous quarter
The debt is 49% less than the equity
Alnylam Pharmaceuticals's debt to equity has soared by 143% YoY and by 89% from the previous quarter
The debt has soared by 72% YoY and by 58% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.